Lack of growth inhibitory synergism with combined MAPK/PI3K inhibition in preclinical models of pancreatic cancer

Ann Oncol. 2017 Nov 1;28(11):2896-2898. doi: 10.1093/annonc/mdx335.

Authors

L Ciuffreda¹, A Del Curatolo², I Falcone³, F Conciatori⁴, C Bazzichetto⁴, F Cognetti³, V Corbo², A Scarpa², M Milella¹

Affiliations

¹ Medical Oncology 1, Regina Elena National Cancer Institute, Rome. Electronic address: ludovicaciuffreda@hotmail.com.
² ARC-Net Research Centre and Department of Pathology, University of Verona, Verona.
³ Medical Oncology 1, Regina Elena National Cancer Institute, Rome.
⁴ Medical Oncology 1, Regina Elena National Cancer Institute, Rome; University of Rome, La Sapienza, Rome, Italy.

PMID: 28666315
DOI: 10.1093/annonc/mdx335

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / pharmacology*
Carcinoma, Pancreatic Ductal / drug therapy*
Carcinoma, Pancreatic Ductal / enzymology*
Carcinoma, Pancreatic Ductal / pathology
Cell Growth Processes / drug effects
Drug Synergism
Heterocyclic Compounds, 3-Ring / administration & dosage
Heterocyclic Compounds, 3-Ring / pharmacology
Humans
MAP Kinase Kinase Kinases / antagonists & inhibitors*
MAP Kinase Kinase Kinases / metabolism
Morpholines / pharmacology
Pancreatic Neoplasms / drug therapy*
Pancreatic Neoplasms / enzymology*
Pancreatic Neoplasms / pathology
Phosphatidylinositol 3-Kinases / metabolism
Phosphoinositide-3 Kinase Inhibitors*
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / pharmacology*
Pyridones / administration & dosage
Pyridones / pharmacology
Pyrimidinones / administration & dosage
Pyrimidinones / pharmacology
Triazines / pharmacology

Substances

Heterocyclic Compounds, 3-Ring
MK 2206
Morpholines
Phosphoinositide-3 Kinase Inhibitors
Protein Kinase Inhibitors
Pyridones
Pyrimidinones
Triazines
trametinib
gedatolisib
MAP Kinase Kinase Kinases